At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,027 enrolled
Drug / intervention
Ixekizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
In Brief
A Phase 4 clinical trial evaluating Ixekizumab, Guselkumab, and 1 other intervention for Plaque Psoriasis. Completed, enrolled 1,027 participants across 124 sites in 3 countries.
Detailed Summary
The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada, Puerto Rico, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartNov 2018
Primary CompletionJul 2019
Study CompletionJan 2020
TodayJul 2026
First PostedJun 29, 2018
Enrollment StartNov 9, 2018
Primary CompletionJul 15, 2019
Study CompletionJan 8, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.0 years ago
Interventions
Ixekizumabdrug
Administered SC
Guselkumabdrug
Administered SC
Placebodrug
Administered SC